Oncology
1 drug is in development for Relapsed/Refractory Multiple Myeloma.
- Companies
- 1
- Clinical trials
- 18
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Relapsed/Refractory Multiple Myeloma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| ALLO-647 | Allogene Therapeutics, Inc. (ALLO) |
About this indication
Relapsed/Refractory Multiple Myeloma context
Oncology·MeSH: Multiple Myeloma (D009101)
Narrower concept of MeSH descriptor Multiple Myeloma
Prevalence
17.0 / 100K
Incidence
7.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Relapsed/Refractory Multiple Myeloma?
BioSniper tracks 1 drug in development for Relapsed/Refractory Multiple Myeloma across 1 company.
How many clinical trials target Relapsed/Refractory Multiple Myeloma?
There are 18 clinical trials targeting Relapsed/Refractory Multiple Myeloma tracked by BioSniper.
What is the prevalence of Relapsed/Refractory Multiple Myeloma?
The estimated prevalence of Relapsed/Refractory Multiple Myeloma is approximately 17.0 per 100,000 population.